1. Home
  2. MATH vs IPHA Comparison

MATH vs IPHA Comparison

Compare MATH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$2.66

Market Cap

145.4M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.95

Market Cap

174.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
IPHA
Founded
2015
1999
Country
Hong Kong
France
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.4M
174.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MATH
IPHA
Price
$2.66
$1.95
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.00
AVG Volume (30 Days)
115.0K
565.1K
Earning Date
12-05-2025
09-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
$44,567,257.00
$14,839,695.00
Revenue This Year
N/A
$22.29
Revenue Next Year
N/A
$43.84
P/E Ratio
$6.63
N/A
Revenue Growth
165.86
N/A
52 Week Low
$0.88
$1.41
52 Week High
$4.17
$3.51

Technical Indicators

Market Signals
Indicator
MATH
IPHA
Relative Strength Index (RSI) 41.92 52.17
Support Level $2.75 $1.81
Resistance Level $3.03 $1.91
Average True Range (ATR) 0.22 0.09
MACD 0.00 0.01
Stochastic Oscillator 30.43 50.00

Price Performance

Historical Comparison
MATH
IPHA

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: